Lv2
120 积分 2025-08-06 加入
Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia
2天前
已完结
Ancient genomic profile of the Shatuo Turkic leader Li Keyong
7天前
已关闭
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs
16天前
已完结
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
17天前
已完结
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia
19天前
已完结
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs
19天前
已完结
Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?
20天前
已完结
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study
21天前
已完结
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
23天前
已完结
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial
23天前
已完结
皖公网安备34019202002308
